Advertisement


Linda R. Mileshkin, MD, MBBS, FRACP, on Puxitatug Samrotecan for Endometrial or Ovarian Cancer

ASCO 2026

Advertisement

Linda R. Mileshkin, MD, MBBS, FRACP, of Peter MacCallum Cancer Centre, shares results from the phase I/IIA BLUESTAR study on the safety and efficacy of puxitatug samrotecan, a B7-H4–directed topoisomerase I inhibitor antibody-drug conjugate, in patients with endometrial cancer or ovarian cancer (Abstract 5515). 



Related Videos

Lymphoma

Dai Chihara, MD, on a Regimen for Older, Unfit, or Frail Patients With Newly Diagnosed DLBCL

Dai Chihara, MD, of The University of Texas MD Anderson Cancer Center, reviews results from an open-label, single-arm, phase II trial that investigated the combination of epcoritamab with R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) classified as unfit or frail per geriatric assessment or not eligible for anthracycline chemotherapy due to reduced ejection function or prior exposure (Abstract 7002). 

Gastrointestinal Cancer

Veronica Diermayr, PhD, on AI-Driven Prediction of N256-Glycosylated CEACAM5/6 Expression in Gastric and Esophageal Cancer

Veronica Diermayr, PhD, of EDDC and A*STAR, discusses the use of artificial intelligence (AI) driven strategy called H&E 2.0 in gastric and esophageal cancer. Researchers tested the feasibility of training deep-learning models on hematoxylin and eosin images of gastroesophageal carcinomas and their ability to predict EBC-129 antigen expression directly from these images. EBC-129 is an experimental antibody-drug conjugate that targets N256-glycosylated CEACAM5/6, which is highly expressed on solid tumors, including gastroesophageal cancers (Abstract 4018).

Skin Cancer

Hannah L. Kenny, MD, and Joseph M. Curry, MD, on BCC of the Head and Neck: Neoadjuvant Cemiplimab

Hannah L. Kenny, MD, and Joseph M. Curry, MD, both of Thomas Jefferson University Hospital, discuss results of a phase II trial of neoadjuvant cemiplimab-rwlc in patients with hedgehog inhibitor–naive basal cell carcinoma (BCC) of the head and neck (Abstract 9515). 

Gastrointestinal Cancer
Gastroesophageal Cancer

Yelena Y. Janjigian, MD, FASCO, on Safety Results From DESTINY-Gastric03

Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center, discusses safety results for DESTINY-Gastric03 Part 2 (arms D and F) and Part 4. The trial evaluated first-line fam-trastuzumab deruxtecan-nxki–based regimens in advanced HER2-expressing gastric cancer, gastroesophageal adenocarcinoma, and esophageal carcinoma (Abstract 4002).

Lung Cancer

Bjorn Henning Gronberg, MD, PhD, on Extensive-Stage SCLC: Concurrent TRT and Chemoimmunotherapy

Bjorn Henning Gronberg, MD, PhD, of St. Olav’s Hospital, discusses findings from a phase III trial of concurrent thoracic radiotherapy (TRT) plus platinum/etoposide chemotherapy and the PD-L1 inhibitor durvalumab in patients with extensive-stage small cell lung cancer (SCLC) (Abstract LBA8005).

Advertisement

Advertisement




Advertisement